Gastroenteritis was reported in 3.1% of patients given the weight loss drug, Belviq (lorcaserin), versus 2% of patients given a placebo according to studies performed leading up to the FDA approval of the drug.
© Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.